New study aims to reduce bleeding risks in liver transplants
NCT ID NCT07265843
First seen Jan 04, 2026 · Last updated Apr 29, 2026 · Updated 17 times
Summary
This study compares two approved blood products—Intercept Fibrinogen Complex and Standard Cryoprecipitate—to see which controls bleeding better during liver transplant surgery. About 60 adults with liver disease who need a transplant will take part. The goal is to improve bleeding management and reduce the need for additional blood products.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT SURGERY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Cincinnati
Cincinnati, Ohio, 45221, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.